METHOD FOR AMELIORATING LIVER FIBROSIS BY USING NANOPARTICLE CONTAINING TYROSINE KINASE INHIBITOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 16, 2016
app pub date -
Mar 2, 2015
filing date -
Dec 11, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention is related to a method for ameliorating liver fibrosis in a subject. The present invention utilizes copolymers of polyethylene glycol and poly (D, L-lactide-co-glycolide) to form nanoparticle composition containing tyrosine kinase inhibitor, such as Sorafenib. The use of nanoparticle composition is non-toxic and can increase the stability and decrease the release of drug in blood circulation. The pharmaceutical composition is in an injectable form. The nanoparticle composition containing tyrosine kinase inhibitor of the present invention can effectively ameliorate liver fibrosis including decreasing extracellular matrix accumulation, suppressing hepatic stellate cell activity, shrinking of abnormal blood vessel, and lowering microvascular density in fibrotic liver; hence is suitable for clinical application for the treatment of liver fibrosis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully